Federal contract award
75A50123C00067
BIOAEGIS: PLASMA GELSOLIN (PGSN), AN ABUNDANT, CIRCULATING PROTEIN MODULATES INFLAMMATION WHILE ALSO ENHANCING HOST DEFENSES BY STIMULATING THE UPTAKE AND KILLING OF PATHOGENS. CLINICAL STUDIES HAVE CONSISTENTLY SHOWN PGSN IS DEPLETED IN SEVERE I
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $20.0M |
| Current contract value | $20.0M |
| Potential contract value / ceiling | $20.0M |
| Start date | Sep 21, 2023 |
| Current end date | Aug 31, 2027 |
| Potential end date | Aug 31, 2027 |
| Latest award activity | Jul 13, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 5 of 5 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 13, 2026 | P00004 | $0 | BIOAEGIS: PLASMA GELSOLIN (PGSN), AN ABUNDANT, CIRCULATING PROTEIN MODULATES INFLAMMATION WHILE ALSO ENHANCING HOST DEFENSES BY STIMULATING THE UPTAKE AND KILLING OF PATHOGENS. CLINICAL STUDIES HAVE CONSISTENTLY SHOWN PGSN IS DEPLETED IN SEVERE I |
| Sep 30, 2025 | P00003 | $0 | BIOAEGIS: PLASMA GELSOLIN (PGSN), AN ABUNDANT, CIRCULATING PROTEIN MODULATES INFLAMMATION WHILE ALSO ENHANCING HOST DEFENSES BY STIMULATING THE UPTAKE AND KILLING OF PATHOGENS. CLINICAL STUDIES HAVE CONSISTENTLY SHOWN PGSN IS DEPLETED IN SEVERE I |
| Jun 10, 2025 | P00002 | $0 | BIOAEGIS: PLASMA GELSOLIN (PGSN), AN ABUNDANT, CIRCULATING PROTEIN MODULATES INFLAMMATION WHILE ALSO ENHANCING HOST DEFENSES BY STIMULATING THE UPTAKE AND KILLING OF PATHOGENS. CLINICAL STUDIES HAVE CONSISTENTLY SHOWN PGSN IS DEPLETED IN SEVERE I |
| May 6, 2025 | P00001 | $0 | BIOAEGIS: PLASMA GELSOLIN (PGSN), AN ABUNDANT, CIRCULATING PROTEIN MODULATES INFLAMMATION WHILE ALSO ENHANCING HOST DEFENSES BY STIMULATING THE UPTAKE AND KILLING OF PATHOGENS. CLINICAL STUDIES HAVE CONSISTENTLY SHOWN PGSN IS DEPLETED IN SEVERE I |
| Sep 21, 2023 | 0 | $20.0M | BIOAEGIS: PLASMA GELSOLIN (PGSN), AN ABUNDANT, CIRCULATING PROTEIN MODULATES INFLAMMATION WHILE ALSO ENHANCING HOST DEFENSES BY STIMULATING THE UPTAKE AND KILLING OF PATHOGENS. CLINICAL STUDIES HAVE CONSISTENTLY SHOWN PGSN IS DEPLETED IN SEVERE I |
Estimated positioning window
Nov 1, 2026 – Feb 28, 2027
70/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 70/100. Available recorded signals: 65 points.
- Contract end 2027-08-31 (303 days from calculation)
- +35 points
- 18 historical awards in this buyer and category group
- +15 points
- 5 recorded award transactions
- +10 points
- Latest award action: 2026-07-13
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.